Ravuconazole
| Title | Journal |
|---|---|
| Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility. | Journal of medicinal chemistry 20140508 |
| Hybrids of ravuconazole: synthesis and biological evaluation. | European journal of medicinal chemistry 20120801 |
| Newer antifungal agents. | Expert review of anti-infective therapy 20110301 |
| In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. | Antimicrobial agents and chemotherapy 20101101 |
| [Recent advances in the study of new antifungal lead compounds]. | Yao xue xue bao = Acta pharmaceutica Sinica 20100801 |
| Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. | Antimicrobial agents and chemotherapy 20100701 |
| Onychomycosis. | Clinics in dermatology 20100304 |
| Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. | Current opinion in investigational drugs (London, England : 2000) 20100201 |
| In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. | Antimicrobial agents and chemotherapy 20090801 |
| Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. | Antimicrobial agents and chemotherapy 20090401 |
| Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. | Journal of clinical microbiology 20080901 |
| In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. | Antimicrobial agents and chemotherapy 20080601 |
| Discovery of novel indazole-linked triazoles as antifungal agents. | Bioorganic & medicinal chemistry letters 20070615 |
| Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. | Antimicrobial agents and chemotherapy 20061201 |
| Multi-azole resistance in Aspergillus fumigatus. | International journal of antimicrobial agents 20061101 |
| Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. | The Journal of infectious diseases 20061001 |
| Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. | Expert opinion on investigational drugs 20060601 |
| In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates. | Mycoses 20060501 |
| The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers. | Journal of clinical pharmacology 20060201 |
| In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. | Antimicrobial agents and chemotherapy 20051201 |
| Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. | The Journal of antimicrobial chemotherapy 20051101 |
| Advances in antifungal therapy. | The Pediatric infectious disease journal 20051001 |
| Antifungal agents in children. | Pediatric clinics of North America 20050601 |
| In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. | Medical mycology 20050501 |
| In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. | Medical mycology 20050301 |
| Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. | Journal of clinical microbiology 20041001 |
| Effects of several antifungal drug combinations against clinical and environmental isolates of Cryptococcus neoformans from China. | Mycoses 20040801 |
| In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. | Diagnostic microbiology and infectious disease 20040201 |
| In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. | Diagnostic microbiology and infectious disease 20040101 |
| In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20031201 |
| Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties. | Bioorganic & medicinal chemistry letters 20031103 |
| Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. | Journal of clinical microbiology 20030801 |
| New antifungal agents. | Dermatologic clinics 20030701 |
| Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. | The Journal of infectious diseases 20030615 |
| In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. | Antimicrobial agents and chemotherapy 20030401 |
| In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. | International journal of antimicrobial agents 20030101 |
| [Present status and future prospects of azole antifungal agents in Japan]. | The Japanese journal of antibiotics 20021201 |
| Laboratory evaluation of new antifungal agents against rare and refractory mycoses. | Current opinion in infectious diseases 20021201 |
| Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals. | Bioorganic & medicinal chemistry letters 20021007 |
| In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. | The Journal of antimicrobial chemotherapy 20020701 |
| In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. | Antimicrobial agents and chemotherapy 20020601 |
| Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole. | Journal of clinical microbiology 20020501 |
| Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. | Antimicrobial agents and chemotherapy 20020401 |
| Ravuconazole Eisai/Bristol-Myers Squibb. | Current opinion in investigational drugs (London, England : 2000) 20020401 |
| Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. | Antimicrobial agents and chemotherapy 20020301 |
| Penetration of ravuconazole, a new triazole antifungal, into rat tissues. | Chemotherapy 20020301 |
| Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. | The Journal of antimicrobial chemotherapy 20020201 |
| Antifungals: what's in the pipeline. | Current opinion in microbiology 20011001 |
| In vitro activities of four novel triazoles against Scedosporium spp. | Antimicrobial agents and chemotherapy 20010701 |
| Effect of ravuconazole, a new triazole antifungal, in a rat intraabdominal abscess model. | Chemotherapy 20010101 |
| Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. | Antimicrobial agents and chemotherapy 20001201 |
| In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. | Antimicrobial agents and chemotherapy 20000201 |
| In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole. | Diagnostic microbiology and infectious disease 19991001 |
| In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. | Antimicrobial agents and chemotherapy 19981201 |
| New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol. | Journal of medicinal chemistry 19980521 |
| New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. | Journal of medicinal chemistry 19980521 |
| In vitro activity of a new oral triazole, BMS-207147 (ER-30346). | Antimicrobial agents and chemotherapy 19980201 |
| In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. | Antimicrobial agents and chemotherapy 19961001 |
| Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. | Antimicrobial agents and chemotherapy 19961001 |